Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
“Anticoagulation Bridging:
A Clinical Summary Every Practitioner Should Know
Navigating perioperative anticoagulation decisions can be complex — but getting it right is critical for patient safety.
Here are the key clinical pearls from the latest evidence and CHEST 2022 Guidelines:
Why Bridging Therapy Exists?
When initiating warfarin, Protein C drops rapidly while Prothrombin (Factor II) persists for 42–72 hours — creating a transient ‘hypercoagulable‘ window.
Overlapping with UFH or LMWH for a minimum of 5 days bridges this gap safely.
The 5-Day Rule
Stop heparin/LMWH ‘only’ when BOTH conditions are met:
- INR ≥ 2.0
- INR therapeutic for ≥ 24 hours (or two consecutive therapeutic readings)
Routine Perioperative Bridging? Not Recommended.
CHEST 2022 states routine heparin bridging is generally Not recommended for most patients — increased bleeding risk with little to no reduction in thromboembolism.
Reserve it for selected high-risk cases: mechanical heart valves, recent VTE < 3 months, or recent arterial thromboembolism.
DOACs: No Bridging Needed.
Their short half-life and rapid onset make perioperative bridging unnecessary.
Always Watch for HIT.
Platelet drop > 50%, typically 5–10 days post-exposure? Suspect Heparin-Induced Thrombocytopenia.
Stop all heparin immediately and switch to a non-heparin anticoagulant (Argatroban, Fondaparinux, or Bivalirudin).
Reversal When It Matters.
- UFH reversal with Protamine Sulfate
- Life-threatening warfarin bleeding reversal with 4-Factor PCC and IV Vitamin K (faster and more sustained than FFP)
Sound anticoagulation management is where pharmacology, clinical judgment, and patient safety converge.
These principles save lives when applied correctly.
What aspect of anticoagulation bridging do you find most challenging in clinical practice? ”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026